AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25515244
Drug: 1% squalamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% squalamine ointment
Trial: 21416311
Drug: Dexmedetomidine IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine IV (0.5 μg/kg bolus over 10 min and 0.5 μg/kg/h infusion) with local anesthesia (lidocaine 2% with epinephrine)
Trial: 21416311
Drug: Epidural anesthesia
RxNorm normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Epidural anesthesia (15 ml of 0.25% bupivacaine + 100 μg fentanyl)
Trial: 16012523
Drug: Concurrent combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent combination chemotherapy and radiotherapy (66 Gy in 33 fractions)
Trial: 16012523
Drug: Concurrent combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent combination chemotherapy and radiotherapy
Trial: 10365740
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (Dalteparin)
Trial: 7486898
Drug: Coca-Cola Classic
RxNorm normalized name: cola extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coca-Cola Classic (240 ml) with ketoconazole (200 mg)
Trial: 7486898
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with ketoconazole (200 mg) (control)
Trial: 7486898
Drug: Water with
RxNorm normalized name: sterile water with electrolytes injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Water with ketoconazole (200 mg) after omeprazole (60 mg)
Trial: 6262930
Drug: Cefazoline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazoline (1 gram) administered 30 minutes before operation
Trial: 21509053
Drug: Sublingual nitroglycerine
RxNorm normalized name: nitroglycerin Sublingual Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual nitroglycerine (NEDV)
Trial: 17103167
Drug: Neoadjuvant radio-chemotherapy
RxNorm normalized name: Valerianae radix
DrugBank: Valerian (DB13196)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant radio-chemotherapy (NARCT)
Trial: 9158268
Drug: Imipramine (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine (0.9 mg/kg for three weeks)
Trial: 7689205
Drug: Sotalol (2.0‐2.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (2.0‐2.9 mg/kg)
Trial: 7689205
Drug: Flecainide (2.5‐3.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flecainide (2.5‐3.3 mg/kg)
Trial: 7689205
Drug: Verapamil (3.3‐3.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (3.3‐3.7 mg/kg)
Trial: 18475293
Drug: Paclitaxel poliglumex
RxNorm normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel poliglumex (PPX) 175 mg m(‐2)
Trial: 18475293
Drug: Paclitaxel poliglumex
RxNorm normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paclitaxel poliglumex (PPX) 210 mg m(‐2)
Trial: 18475293
Drug: Docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel 75 mg m(‐2)
Trial: 12355999
Drug: Thiazide‐like diuretic,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiazide‐like diuretic, slow‐release indapamid
Trial: 12355999
Drug: Converting enzyme
RxNorm normalized name: Prohormone converting enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Converting enzyme inhibitor, enalapril 20 mg
Trial: 10692717
Drug: Sumatriptan 50
RxNorm normalized name: sumatriptan 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 50 mg tablets
Trial: 6416805
Drug: 2% nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% nitroglycerin ointment (2 cm/m2 body surface)
Trial: 6416805
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 2% nitroglycerin ointment and 50 mg atenolol
Trial: 30986326
Drug: Rotary NiTi
RxNorm normalized name: Rytary
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rotary NiTi to size 20, .04 taper with syringe and needle (SNI)
Trial: 30986326
Drug: Rotary NiTi
RxNorm normalized name: Rytary
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rotary NiTi to size 20, .04 taper with ultrasonically activated irrigation (UAI)
Trial: 30986326
Drug: Rotary NiTi
RxNorm normalized name: Rytary
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rotary NiTi to size 40, .04 taper with syringe and needle (SNI)
Trial: 30986326
Drug: Rotary NiTi
RxNorm normalized name: Rytary
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Rotary NiTi to size 40, .04 taper with ultrasonically activated irrigation (UAI)
Trial: 27714530
Drug: Ginger (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ginger (500 mg) twice daily for 5 days starting on the first day of the second AC cycle
Trial: 27714530
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 5 days starting on the first day of the second AC cycle
Trial: 26045831
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg intravenous injection for 20 min)
Trial: 23555741
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of IIV
Trial: 23555741
Drug: LAIV-IIV administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: LAIV-IIV administration
Trial: 21651947
Drug: SII HibP(RO)
RxNorm normalized name: phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SII HibP(RO) vaccine manufactured at industrial scale
Trial: 21651947
Drug: SII HibP(RO)
RxNorm normalized name: phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SII HibP(RO) vaccine manufactured at small scale
Trial: 11213940
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium bromide infusion at 10 microg/kg/min for 24 to 120 hours after a bolus of 0.6 mg/kg
Trial: 11213940
Drug: Rocuronium bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rocuronium bromide infusion
Trial: 2967665
Drug: Mucopolysaccharide polysulphate
RxNorm normalized name: mucopolysaccharide polysulfate
DrugBank: Mucopolysaccharide polysulphate (DB16564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mucopolysaccharide polysulphate (MPS) cream applied twice daily
Trial: 2967665
Drug: Cream base
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream base (control) applied twice daily
Trial: 21804130
Drug: torcetrapib plus
RxNorm normalized name: Torcetrapib
DrugBank: Torcetrapib (DB06281)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: torcetrapib plus atorvastatin
Trial: 28974520
Drug: atorvastatin only
RxNorm normalized name: Atorvastatin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atorvastatin only
Trial: 27780197
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 200 mg/kg buccal 40% dextrose gel
Trial: 12931275
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (0.3 U/kg 125I‐insulin glargine)
Trial: 12931275
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (0.3 U/kg 125I‐NPH insulin)
Trial: 8617707
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 to 200 mg daily for 10 days)
Trial: 8617707
Drug: Carbamazepine (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (200 mg once daily for 2 days, then every 12 hours)
Trial: 8617707
Drug: Carbamazepine plus
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamazepine plus Sertraline
Trial: 31571176
Drug: Intraventricular alteplase
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraventricular alteplase injections (n=251)
Trial: 31571176
Drug: Saline (placebo)
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline (placebo) injections (n=249)
Trial: 30824955
Drug: Doripenem (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doripenem (1.0 g every 8 h)
Trial: 30824955
Drug: Meropenem (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meropenem (1.0 g every 8 h)
Trial: 21324135
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose olanzapine LAI (150 mg/2 weeks)
Trial: 21324135
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose olanzapine LAI (405 mg/4 weeks)
Trial: 21324135
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose olanzapine LAI (300 mg/2 weeks)
Trial: 21324135
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose olanzapine LAI
Trial: 21324135
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose olanzapine LAI
Trial: 21324135
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose olanzapine LAI
Trial: 21324135
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of olanzapine LAI
Trial: 18852332
Drug: Oral glucose
RxNorm normalized name: glucose Oral Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral glucose (28 g)
Trial: 12791116
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (500 micro g.kg-1 i.v. ketamine preincision and a ketamine infusion at 4 micro g.kg-1 min-1 postoperatively)
Trial: 12791116
Drug: Ketamine bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine bolus (500 micro g.kg-1 i.v. ketamine preincision and a saline infusion postoperatively)
Trial: 12791116
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline infusion postoperatively)
Trial: 23569309
Drug: Maintenance chemotherapy
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance chemotherapy with paclitaxel/gemcitabine (PG)
Trial: 12512035
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment for 1 year
Trial: 12512035
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment for 2 additional years
Trial: 12512035
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment for 3 years
Trial: 1904989
Drug: Intravenous immune
RxNorm normalized name: Intravenous immune globulin (human)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immune globulin therapy at a dose of 400 mg per kilogram every three weeks
Trial: 1904989
Drug: No immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No immune globulin therapy (Control)
Trial: 7046774
Drug: labetalol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol monotherapy (329 mg daily for 12 weeks)
Trial: 7046774
Drug: labetalol combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol combined with diuretics (374 mg daily for 12 weeks)
Trial: 7046774
Drug: labetalol monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol monotherapy (260 mg daily for 6 months or longer)
Trial: 7046774
Drug: labetalol combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: labetalol combined with diuretics (450 mg daily for 6 months or longer)
Trial: 26255456
Drug: Ondansetron 8
RxNorm normalized name: ondansetron 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 8 mg i.v. dissolved in 10 ml 0.9% NaCl
Trial: 26255456
Drug: Placebo (0.9%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.9% NaCl 10 mg)
Trial: 15291907
Drug: Oral desensitization
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral desensitization with increasing doses of cow's milk starting from 0.06 mg of CM proteins
Trial: 11292409
Drug: Ganciclovir implant
RxNorm normalized name: ganciclovir Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganciclovir implant plus oral ganciclovir (1 gm three times daily)
Trial: 11292409
Drug: Intravenous cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous cidofovir (5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week)
Trial: 28107143
Drug: Clarithromycin 5
RxNorm normalized name: clarithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 5 mg/kg daily for 4 weeks
Trial: 18294337
Drug: Chloroquine (CQ)
RxNorm normalized name: Chloroquine
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chloroquine (CQ) + Sulfadoxine/Pyrimethamine (SDx/PYR) combination
Trial: 18294337
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of CQ + SDx/PYR
Trial: 18294337
Drug: Full-strength CQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-strength CQ + SDx/PYR combination
Trial: 14608559
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug and acupressure bands
Trial: 14608559
Drug: Placebo drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo drug and placebo bands
Trial: 7745195
Drug: Ice applied
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ice applied to subcutaneous heparin injection sites
Trial: 7114515
Drug: Cimetidine (therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (therapy group)
Trial: 7114515
Drug: Placebo (therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (therapy group)
Trial: 25332474
Drug: Dairy diet
RxNorm normalized name: Beano Dairy Defense
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dairy diet (3 servings/d: 375 mL low-fat milk, 175 g low-fat yogurt, 30 g regular-fat cheddar cheese)
Trial: 23053790
Drug: Total testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Total testosterone (ng/mL)
Trial: 23053790
Drug: SHBG (nmol/L)
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHBG (nmol/L)
Trial: 23053790
Drug: Free estradiol
RxNorm normalized name: Free estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Free estradiol (fg/mL)
Trial: 20173425
Drug: Distributed form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Distributed form of constraint‐induced therapy
Trial: 18809812
Drug: 25% energy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% energy deficit by a combination of CR and increased aerobic exercise (CR + EX group)
Trial: 19900349
Drug: Haloperidol (2-40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (2-40 mg)
Trial: 12389342
Drug: Control pediculicide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control pediculicide spray containing permethrin, malathion, piperonyl butoxide, isododecane, and propellant gas; applied twice for 10 minutes with a 10-day interval between applications.
Trial: 7605863
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once a day for 2 weeks (Group 1)
Trial: 7605863
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once a day for 4 weeks (Group 2)
Trial: 7605863
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg twice a day for 2 weeks (Group 3)
Trial: 7605863
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg twice a day for 4 weeks (Group 4)
Trial: 2194694
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy combined with ticlopidine 250 mg b.i.d. (group C + T)
Trial: 26517
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg mequitazine twice daily
Trial: 6983839
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg disoprofol
Trial: 6983839
Drug: 3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/kg disoprofol
Trial: 3877474
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg thiopentone
Trial: 6983839
Drug: 6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/kg thiopentone
Trial: 6983839
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg methohexitone
Trial: 22305678
Drug: Pneumovax (23-valent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pneumovax (23-valent pneumococcal polysaccharide vaccine)
Trial: 20819223
Drug: Manipulative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative therapy (manipulation and mobilization) in addition to usual medical care (UMC)
Trial: 20819223
Drug: Manipulative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulative therapy (manipulation and mobilization)
Trial: 16222074
Drug: Repeated thermal
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated thermal stimuli on the same side for five daily sessions (Study 1)
Trial: 16222074
Drug: Thermal stimuli
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal stimuli restricted to one side for four daily sessions, then applied to the other side on the fifth session (Study 2)
Trial: 14566490
Drug: Single-lumen tube
RxNorm normalized name: Sus scrofa fallopian tube preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-lumen tube (SLT) with intrathoracic CO2 insufflation at a rate of 0.5-1 l.min(-1) and sustained intrathoracic pressure at 6 mmHg
Trial: 10101653
Drug: CT-guided intratumoral
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided intratumoral gene therapy (10 ml of a vector solution with replication-defective adenovirus containing wild-type p53 cDNA)
Trial: 10101653
Drug: CT-guided intratumoral
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided intratumoral gene therapy (2 ml aliquots injected into different tumor areas)
Trial: 10101653
Drug: CT-guided intratumoral
RxNorm normalized name: brompheniramine tannate Chewable Tablet [BroveX CT]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CT-guided intratumoral gene therapy
Trial: 224958
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate or oral fluphenazine
Trial: 27275351
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg doxycycline once daily for 30 days
Trial: 27275351
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg doxycycline twice daily for 75 days
Trial: 16641904
Drug: Chemoradiotherapy (docetaxel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (docetaxel 20 mg m(‐2) once weekly every 6 weeks + radiotherapy 2 Gy for 5 days a week, total 60 Gy)
Trial: 12695290
Drug: Propranolol (beta-blockers)
RxNorm normalized name: beta-Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propranolol (beta-blockers)
Trial: 11063789
Drug: m‐CPP (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: m‐CPP (0.5 mg/kg)
Trial: 3530933
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg E2V
Trial: 23268187
Drug: 72 hours
RxNorm normalized name: PATCH, TRANSDERMAL 72 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72 hours of perioperative antimicrobial therapy
Trial: 23268187
Drug: 120 hours
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 hours of perioperative antimicrobial therapy
Trial: 18617385
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine 15 mg
Trial: 18617385
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine 10 mg with sufentanil 5 micrograms
Trial: 10891645
Drug: Ethanol (0.7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ethanol (0.7 g of ethanol/kg body weight)